Linaclotide

Quick links to important sections

Linaclotide

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Linaclotide

Quick Facts

Property Description
Active ingredient Linaclotide
Form Hard capsule (oral)
Pharmacological class Guanylate Cyclase-C (GC-C) Agonist
Common purpose Relief from persistent constipation symptoms
Origin Synthetic 14-amino acid peptide

What Type of Medicine is Linaclotide?

Linaclotide is a synthetic 14-amino acid peptide classified as a Guanylate Cyclase-C (GC-C) agonist, representing a highly targeted pharmaceutical approach to modulating intestinal function. This single-ingredient compound, chemically manufactured to mimic the action of endogenous peptides, is the active substance known by the International Nonproprietary Name (INN) Linaclotide.

The drug is specifically recognized for its role as a guanylate cyclase C agonist. This classification highlights the drug’s intended use as a dedicated agent for facilitating relief from functional bowel symptoms. It is prepared for oral use as a hard capsule, ensuring the peptide is delivered directly to the intestinal tract.

Linaclotide's Unique Composition and Action

Linaclotide is designed for minimal systemic absorption, ensuring the active substance and its primary metabolite function locally within the gastrointestinal tract. This localized mechanism is a key differentiating feature, ensuring the drug’s primary influence is restricted to the gut lining where it binds to the GC-C receptor.

The compound's profile is characterized as a treatment with low systemic exposure. The drug’s minimal systemic exposure reduces the potential for widespread drug effects throughout the body. The compound primarily restricts its influence to the gut lining, where its action is concentrated to modulate local physiology.

What is the General Purpose of Linaclotide?

The general purpose of Linaclotide is to provide relief from the core symptoms of persistent constipation by facilitating the softening of stool and accelerating gastrointestinal transit. The receptor activation triggered by the GC-C agonist initiates increased fluid and electrolyte secretion into the intestinal lumen. This therapeutic outcome is aimed at alleviating chronic abdominal discomfort and feelings of incomplete evacuation, offering relief in scenarios where other general measures have proven insufficient.

Regulatory References

  1. U.S. National Library of Medicine

What side effects are possible with Linaclotide?

Possible side effects and safety information

The safety profile of Linaclotide is primarily defined by reactions occurring within the Gastrointestinal System, consistent with the drug's intended localized action. All documented adverse reactions are based on official regulatory sources, with frequencies derived from controlled clinical trials.

Common Adverse Reactions

The most frequently reported adverse reaction is Diarrhea, which is classified as Very Common (occurring in 1/10 patients) in regulatory documents. This effect often begins within the first two weeks of treatment initiation. Other adverse reactions documented as Common (occurring in 1/100 to < 1/10 patients) include abdominal pain, flatulence, and abdominal distension (bloating). Non-gastrointestinal events reported in the Common classification include headache and certain infections, such as viral gastroenteritis.


Documented Serious Safety Patterns

Linaclotide is associated with the potential for severe diarrhea, which may lead to systemic safety concerns. Consequences such as dehydration and imbalances like hypokalemia (low potassium) are documented as Uncommon adverse reactions. In post-marketing experience, Gastrointestinal Perforation has been reported as a Rare serious event.

Population-Specific Safety Considerations

Linaclotide is contraindicated in pediatric patients less than 2 years of age due to an elevated risk of serious dehydration. In patients 65 years of age, the occurrence of diarrhea was reported more frequently during clinical trials. Due to minimal systemic exposure, the regulatory label states that no dose adjustment is required for patients with any degree of renal or hepatic impairment. Additionally, the medicine is contraindicated in all age groups for patients with known or suspected mechanical gastrointestinal obstruction.

Overdose and Emergency Response

The official regulatory documentation for Linaclotide indicates that overdose is primarily associated with an exaggeration of the drug’s intended effect. The most common and documented clinical sign of taking too much Linaclotide is severe diarrhea.

Manifestations and Severe Outcomes

The severity of an overdose is intrinsically linked to the consequences of fluid loss. Severe diarrhea may lead to dehydration and subsequent significant electrolyte abnormalities, such as hypokalemia or hyponatremia. In documented cases, complications associated with severe fluid loss have included hypotension (low blood pressure) and syncope (fainting), which can require hospitalization.

When to Seek Immediate Medical Help

Patients must seek immediate medical attention or contact emergency services if severe diarrhea or any signs of dehydration occur. In the event of a suspected overdose, the use of Linaclotide must be discontinued. The official labeling states that no specific antidote is known for Linaclotide.

Required Supportive Management

Management is limited to symptomatic and supportive treatment. This often includes careful monitoring of fluid and electrolyte balance. In severe cases, procedures such as rehydration, potentially including intravenous fluid administration, may be required. Regulatory documents note that special caution regarding fluid balance is relevant for vulnerable populations, including the elderly and certain pediatric patients where the risk of serious dehydration is emphasized.

Therapeutic Uses of Linaclotide

What Linaclotide Treats: Main Uses and Benefits

Linaclotide is a medicine used to provide symptomatic relief in patients diagnosed with certain chronic functional bowel disorders. The primary therapeutic focus for this medication is the management of these persistent conditions.

It is commonly used in adults for managing Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation (IBS-C), and is also applied for the treatment of functional constipation in pediatric patients aged 6 to 17 years. This medication is commonly applied in situations where symptoms have been long-term and persistent.

The support provided by this treatment helps address the core symptoms that interfere with daily functioning, specifically infrequent and difficult stool passage, chronic abdominal pain, and distension (bloating). It contributes to easing the overall symptom load and supports improved day-to-day comfort.

Improving Stool Frequency and Consistency

This medication provides supportive relief by addressing physical symptoms such as hard stools, assisting with easier evacuation, helping with the reduction of straining, and supporting frequency of spontaneous bowel movements. This assists patients during difficult episodes.

Quick Fact: Relief for Chronic Symptoms
Primary Focus Chronic constipation syndromes and associated abdominal distress.
Symptom Goal Supported frequency of spontaneous bowel movements.
Additional Benefit Relief from persistent abdominal pain and bloating.

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Linaclotide?

Eligibility for Linaclotide is strictly defined by regulatory documents, which establish absolute contraindications and specific age and comorbidity restrictions. The medicine is contraindicated in two main populations: patients with known or suspected mechanical gastrointestinal obstruction and pediatric patients younger than 2 years of age. The exclusion for infants is due to the risk of serious dehydration.

Eligibility Scope

Category Official Regulatory Status (Consolidated)
Populations for whom use is allowed Adults ( ge 18 years) for IBS-C and CIC. Pediatric patients 6–17 years for Functional Constipation (FC) and ge 7 years for IBS-C (US).
Populations for whom use is contraindicated Patients with mechanical GI obstruction and pediatric patients < 2 years.
Organ Function No dose adjustment is required for patients with renal or hepatic impairment.
Pregnancy and Lactation Status Use during lactation is acceptable; the drug and its metabolite are negligibly absorbed and not detectable in human milk.

Connection to the Overall Eligibility Profile

The regulatory profile creates clear boundaries: Linaclotide is prohibited in individuals with gastrointestinal blockage or in infants due to dehydration risk. For other populations, the medicine is established for adults and specific pediatric age groups (US). The absence of systemic absorption means eligibility is not restricted by renal or hepatic function, a key feature noted in labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Linaclotide has minimal systemic absorption, meaning it acts locally in the gastrointestinal tract and is not expected to cause conventional systemic drug-drug interactions. In studies, linaclotide showed no relevant interaction with the cytochrome P450 enzyme system or major drug transporters (like P-gp).

The primary documented interactions are pharmacodynamic and relate to the drug’s local effect on the gut. Concomitant use with other medicinal products that affect bowel function requires caution:


Documented Interaction Categories

Interaction Type Practical Implication
Additive GI Effects Use with other laxatives, PPIs, or NSAIDs may increase the risk of diarrhea.
Reduced Efficacy of Co-administered Drugs Severe or prolonged diarrhea may reduce the absorption and efficacy of other oral medications, particularly those with a narrow therapeutic index (e.g., levothyroxine).
Food Interaction Must be taken on an empty stomach at least 30 minutes before the first meal of the day; a high-fat meal can increase adverse GI events.

Population-Specific Note: Linaclotide is contraindicated in patients under 2 years of age due to the risk of serious dehydration. Additionally, elderly patients may be at a higher risk of diarrhea, which necessitates careful consideration of electrolyte balance.

Mechanism of Action

Linaclotide functions as a selective agonist for the Guanylate Cyclase-C (GC-C) receptor, which is located exclusively on the luminal surface of intestinal epithelial cells. This interaction initiates a dual, localized mechanism to modulate enteric pathways, resulting in increased secretion and modulated afferent nerve signaling.


Fluid Secretion and Motility Cascade

The binding of linaclotide to GC-C increases the intracellular production of cyclic guanosine monophosphate (cGMP). This elevated cGMP activates a kinase cascade that phosphorylates and opens the CFTR ion channel. The resulting secretion of chloride and bicarbonate ions into the intestinal lumen creates an osmotic gradient, drawing water into the bowel. This physiological effect increases intestinal fluid volume, which accelerates gastrointestinal transit and alters stool consistency.


Modulation of Visceral Sensory Nociception

The GC-C activation also causes cGMP to be transported into the submucosal space, where the resulting elevated extracellular cGMP acts locally to modulate peripheral colonic nociceptors (pain-sensing nerves). This mechanistic action decreases the functional activity and sensitivity of these afferent nerves, which results in modulation of afferent sensory signaling and decreased visceral sensory responsiveness. Linaclotide's effect is strictly peripheral and highly localized, as the peptide is minimally absorbed into systemic circulation.

Dosage and Administration Information

How to Use Linaclotide

Linaclotide is an oral medicine administered as a hard capsule, with the specific dose determined by the patient's approved clinical condition. The medicine must be taken once daily at approximately the same time each day to ensure a consistent administration schedule.

Indication (Adults) Recommended Dosage
IBS-C (Irritable Bowel Syndrome with Constipation) 290 micrograms (mcg) once daily
CIC (Chronic Idiopathic Constipation) 145 mcg once daily, or 72 mcg once daily based on individual tolerability

Procedural Constraints and Timing

Administration is strictly defined by a time relationship with food. The capsule must be taken on an empty stomach, at least 30 minutes prior to the first meal of the day. The medicine is generally intended for long-term use, though the necessity for continued treatment is periodically evaluated.

For proper use, the capsule must be swallowed whole and must never be crushed or chewed. For patients unable to swallow the capsule, the contents (beads) can be sprinkled into a small amount of water or applesauce for immediate oral consumption, or administered via a nasogastric or gastrostomy tube. If a dose is missed, instructions advise the patient to skip the missed dose and resume the regular schedule without taking two doses at the same time. No dose adjustment is required for older adults or patients with renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence Overview

This section summarizes the structure of the official research, primarily randomized controlled trials (RCTs), that explored the research landscape for Linaclotide. It outlines the types of studies available, the specific symptoms and outcomes they monitored, and where research limitations or uncertainties remain, without providing any clinical guidance.


Evidence for use in Irritable Bowel Syndrome with Constipation (IBS-C) in Adults

Research exploring the use of Linaclotide for IBS-C has primarily involved large-scale, double-blind, placebo-controlled RCTs. These pivotal studies were applied in populations of adult patients diagnosed with IBS-C. In these trials, researchers primarily measured a strict, regulatory-defined Combined Responder Endpoint. This required tracking reported levels of abdominal pain and the frequency of Complete Spontaneous Bowel Movements (CSBMs) over defined time frames. Controlled research focusing on the durability of the observed patterns typically extends only to the intermediate term (around six months). Comparative evidence is lacking for trials directly comparing this medication against other active prescription treatments.


Evidence for use in Chronic Idiopathic Constipation (CIC) in Adults

Evidence related to Linaclotide’s use for CIC is derived from multiple, well-controlled, placebo-controlled RCTs in adult patients. These studies primarily examined physiological outcomes reflecting daily functioning. The main focus of these trials was the measurement of a regulatory-defined Overall CSBM Responder Endpoint, which required patients to meet specific criteria related to the frequency and increase of CSBMs. Studies monitored patterns related to CSBM frequency rates in the intervention group compared to the comparison group over the course of the pivotal trial period. One area where data are still emerging is controlled research focusing on the persistence of observed outcomes, which is largely restricted to short-term follow-up periods (typically le 12 weeks).


Evidence for use in Functional Constipation in Children and Adolescents (Ages 6–17)

For Functional Constipation (FC) in children and adolescents, the evidence base is primarily derived from a single pivotal Phase 3 RCT. This research was conducted in pediatric patients aged 6 to 17 years who met modified criteria for FC. The study primarily monitored the weekly Spontaneous Bowel Movement (SBM) frequency rate compared to baseline over the 12-week treatment interval. No efficacy or safety data from controlled trials are available for children under 6 years of age.

Key Studies & References Linaclotide for treatment of irritable bowel syndrome with constipation: a randomized, controlled trial and its extension (IBS-C Pivotal Study)

Frequently Asked Questions (FAQ)

Common questions about Linaclotide (FAQ)


Q: Is Linaclotide the same thing as a laxative?

Linaclotide is classified as a Guanylate Cyclase-C (GC-C) agonist, which is a targeted class of medicine. This compound works locally in the digestive tract to increase fluid secretion and accelerate the movement of contents through the bowel. Official product information describes this specific mechanism of action as distinct from how many traditional laxatives operate.


Q: Can I take Linaclotide if I only have occasional constipation, not diagnosed IBS?

According to official regulatory documents, Linaclotide is specifically indicated for chronic conditions: Irritable Bowel Syndrome with Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC) in adults. It is also approved for Functional Constipation (FC) in specific pediatric patients. The medicine is not approved for use in cases of occasional or short-term constipation.


Q: Does Linaclotide have to be taken exactly 30 minutes before the first meal?

Official instructions state that the medicine should be taken on an empty stomach at least 30 minutes before the first meal of the day. Regulatory documents note that taking the medicine after a high-fat meal may increase the likelihood of gastrointestinal side effects, such as loose stools.


Q: Is it safe to use Linaclotide while pregnant?

Linaclotide is designed for minimal absorption into the bloodstream. Regulatory documents state that available human data are insufficient to fully determine any drug-associated risk for major birth defects or miscarriage.


Q: Is it common to have diarrhea after starting Linaclotide?

Diarrhea is documented as the most frequently reported adverse reaction in clinical trials and is classified as Very Common (occurring in ge 1 out of 10 patients). According to official product information, this effect often begins within the first two weeks of starting the medicine.


Q: Are the initial side effects, like gas, likely to go away after a few weeks?

Common mild side effects, which include abdominal pain and gas (flatulence), may be temporary. Studies indicate these events typically follow a short-term course and may last for a period of a few days to a few weeks after treatment initiation.


Q: Does Linaclotide help with pain associated with IBS-C?

Yes, for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C), Linaclotide is researched for its effect on both constipation and associated abdominal pain. Official product information notes that the drug's local action helps to modulate the sensitivity of pain-sensing nerves in the intestine.


Q: Is it safe to use Linaclotide while breastfeeding?

Use of Linaclotide during breastfeeding is described as acceptable in official documents. Because the drug is negligibly absorbed into the bloodstream, it is not expected to result in exposure to the breastfed infant, and the drug and its active metabolite are typically not detectable in human milk.


Q: Can Linaclotide cause weight changes?

Based on the findings from controlled clinical trials, weight changes (either weight gain or weight loss) were not reported as being a common or severe adverse reaction associated with the use of Linaclotide.


Q: Does Linaclotide treat the underlying cause of IBS or just the constipation?

Linaclotide is indicated for the symptomatic treatment of its approved conditions, which means it is designed to provide relief from core symptoms like chronic constipation and abdominal pain. The medicine works locally to modulate intestinal function and accelerate bowel transit.


Q: Is Linaclotide available over the counter?

Linaclotide is designated as a prescription-only medicine by regulatory bodies and is not available for purchase over the counter.


Q: What does 'functional constipation' mean when talking about this drug?

Functional Constipation (FC) is a term used in regulatory documents as an approved indication for Linaclotide in specific pediatric patients. This condition generally describes persistent constipation that does not have a recognizable physical or structural cause, such as a known blockage in the bowel.


Q: Are the side effects of Linaclotide permanent?

While the occurrence of side effects can vary by individual, most common adverse reactions, such as flatulence and diarrhea, are generally described as temporary. Official clinical information suggests these events may follow a course of a few days to a few weeks after treatment begins.


Q: Is Linaclotide a controlled substance?

Linaclotide is a prescription medicine but is not classified as a controlled substance under the Controlled Substances Act in the United States.


Q: Can older adults use Linaclotide safely?

Regulatory documents state that no dose adjustment is required specifically due to a patient's age. However, clinical studies observed that diarrhea was reported more frequently in patients aged 65 years and older. This higher incidence is a factor noted in official documents due to the potential for dehydration in this population.


Q: Do caffeine or alcohol affect how Linaclotide works?

Regulatory information states there are no known interactions between Linaclotide and alcohol. However, because both the medicine and alcohol can separately contribute to effects like diarrhea, there is a potential for a greater likelihood of gastrointestinal side effects when consumed together. The official labeling does not specifically address caffeine.


Q: Can Linaclotide be taken with antacids or heartburn medicine?

While systemic drug-drug interaction is not expected due to minimal absorption, official labeling cautions about taking Linaclotide with medicines that also affect bowel function. The combination with other laxatives or certain antacids (such as those containing magnesium) may result in an additive effect and increase the likelihood of diarrhea.


Q: Will Linaclotide help with bloating or just bowel movements?

Linaclotide is studied for its ability to relieve several core symptoms associated with its indicated conditions. In addition to measuring changes in bowel movement frequency, clinical trials also included the monitoring of related abdominal symptoms, such as bloating (abdominal distension) and abdominal pain.


Q: What are the most common reasons a doctor would prescribe Linaclotide over another drug?

Linaclotide is categorized as a Guanylate Cyclase-C (GC-C) agonist, a targeted type of medicine with a distinct mechanism. This unique action, which is localized in the gut, is described in official documents as both increasing fluid secretion to help bowel movements and modulating the activity of pain-sensing nerves in the intestine.


Q: Can Linaclotide affect blood pressure or heart rate?

Due to the minimal absorption of the drug into the bloodstream, direct cardiovascular effects are generally not expected. However, Orthostatic Hypotension (low blood pressure upon standing) was documented as an Uncommon side effect in trials. Severe diarrhea is a known risk that can potentially lead to dehydration and electrolyte imbalance, which are systemic issues noted in official warnings.


Q: Do I need to change my diet while taking Linaclotide?

The primary dietary constraint documented in official instructions is the timing of administration: the capsule must be taken on an empty stomach at least 30 minutes before the first meal. Regulatory documents specifically note that taking the medicine immediately after a high-fat meal may increase the risk of gastrointestinal side effects.


Q: Can I take fiber supplements along with Linaclotide?

The official labeling advises caution when taking Linaclotide with other medicinal products that influence bowel function, which may include fiber supplements (bulk-forming agents). This is because combining them with Linaclotide may result in an additive effect, increasing the overall likelihood of diarrhea.


Q: Is there a maximum time someone is allowed to take Linaclotide?

The regulatory labeling notes that the duration of use is not limited, meaning the medicine is generally intended for long-term administration. The necessity for continued treatment is, however, typically evaluated periodically.


Q: Can Linaclotide interact with supplements like St. John's Wort?

Because Linaclotide is minimally absorbed into the bloodstream, it is not anticipated to cause the type of systemic interactions that can occur with many other medicines. Official documents emphasize the importance of providing a complete list of all supplements, herbal products, and other medicines being used to a healthcare provider.


Q: Does the time of day I take Linaclotide matter?

Official instructions require the drug to be taken once daily at approximately the same time each day to maintain a consistent administration schedule. The most critical timing constraint documented in the labeling is the requirement to take the capsule on an empty stomach at least 30 minutes before the first meal.


Q: Can Linaclotide cause headaches or joint pain?

Official product information lists headache as a Common adverse reaction documented in clinical trials. Joint pain is not listed among the commonly or severely reported side effects observed in regulatory clinical research.


Q: Are there different doses of Linaclotide, and why are they used?

Linaclotide is available in different strengths, which are indicated for different conditions (e.g., one strength for IBS-C and multiple strengths for CIC). For Chronic Idiopathic Constipation, the lower dose is available to provide efficacy while potentially offering a lower rate of the most common adverse reaction, diarrhea.

How should Linaclotide be stored and disposed of?

Storage and Disposal of Linaclotide

Linaclotide capsules must be stored at controlled room temperature, typically 25 C (77 F), with excursions permitted to 15 C to 30 C. It is essential to protect the medication from moisture and excessive heat; therefore, the capsules must be kept in the original bottle with the child-resistant closure tightly closed and the desiccant packet intact.

Stability and Handling

The medicine must be kept out of the reach and sight of children. If the capsule contents are mixed with applesauce, water, or administered via a nasogastric tube, the prepared mixture must be consumed or administered immediately and must not be stored for later use.

Disposal

To ensure proper disposal, unused or expired linaclotide should be discarded according to local regulations or via a drug take-back program. The medication must not be flushed down the toilet or poured into a drain to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Linaclotide found in:

A-Z Index: